
The tension between technological innovation and consumer protection has long dominated the digital health regulatory landscape.
As an attorney, I’m often privy to innovators’ concerns that enhanced regulation could stifle innovation, particularly in emerging markets. While it’s no secret that heavy-handed regulation could discourage desirable innovation, it’s also important to recognise the beneficial role that regulation plays for both consumers and innovators.
Given the constantly evolving femtech environment, many founders wonder how they can drive meaningful regulatory outcomes without creating unnecessary hurdles along their path to commercialisation. I believe femtech innovators can accomplish this objective by developing public-private partnerships with regulators to shape the future of women’s health regulation.
The first step to developing a meaningful public-private partnership with government regulators is to honestly identify and acknowledge the shortcomings in our beloved femtech industry.
In a world where start-up economics drive product development, it’s necessary to take a step back and identify the harms that lax regulatory frameworks can have on consumers of femtech products. By proactively pinpointing areas in which femtech is not living up to its potential, founders and femtech advocates can help shape future regulatory agendas.
In my opinion, there are at least two key areas of femtech that could benefit from enhanced regulatory oversight. The first area is data privacy, particularly in countries like the US, which do not have comprehensive privacy legislation.
Following the overturn of Roe v. Wade, many consumers lost trust in the femtech industry and deleted their femtech applications. This loss of trust was not only fueled by the lack of national privacy standards in the US, but also stemmed from companies’ downstream data sales to third parties—such as data brokers and social media giants.
To date, there has been little recognition that the heightened sensitivity of reproductive health data demands heightened data protection regulations, and many femtech apps operate in a regulatory void.
The second area craving regulation concerns the review and approval of femtech devices for accuracy before they hit the market.
While the majority of femtech companies offer consumer devices, applications, and software, many of these products are not subject to regulatory scrutiny (such as review by the Food and Drug Administration) because of the generally low risks they pose to consumers.
This means that a significant number of software-based femtech devices are not reviewed or regulated by government agencies prior to launch. This lack of pre-launch review means that many femtech devices are not required to satisfy safety and accuracy standards and that inaccurate devices can flood the market.
For example, the Organization for the Review and Care of Health Apps found that 85 per cent of the femtech industry’s most downloaded apps did not meet quality thresholds and had significant clinical assurance concerns. Yet, consumers have no method of vetting these femtech products or meaningfully choosing between accurate and inaccurate devices.
Acknowledging the need for heightened regulatory oversight of data privacy and device accuracy can benefit both consumers and femtech companies.
Consumers benefit by having stricter standards in place to protect their sensitive health data and ensuring a threshold level of device accuracy. This allows consumers to regain trust in the very industry that is meant to empower them.
Femtech companies, in turn, benefit not only from increased product adoption that accompanies enhanced consumer trust, but also from the fact that privacy and accuracy can now become market and product differentiators.
Companies that build privacy-centric and accurate products can capture significant market share by aligning their product designs with consumer values. This also helps to discourage “get rich quick” innovation in women’s health by companies that are not dedicated to women’s wellbeing.
Once femtech founders and advocates identify and acknowledge areas that are ripe for regulatory oversight, they should partner with the appropriate government entities to develop regulatory agendas in these areas.
Public-private partnerships are necessary to avoid top-down regulatory efforts that can inadvertently ignore the realities associated with developing, marketing, and scaling femtech products. Top-down regulation involves regulatory agendas set solely by government agencies, who oftentimes lack on-the-ground experience and expertise that founders and advocates bring to the table.
Collaboration can result in mutually beneficial outcomes, as the public and private sectors can capitalise on each other’s strengths and experiences to build the future of women’s health innovation together. When the femtech industry becomes an active participant in regulatory activities, it can integrate diverse perspectives and resources into the conversation and help develop solutions that can quickly adapt to technological change without stifling future femtech innovation.
In a world of constant change, I fully believe that femtech founders and advocates should be at the forefront of regulatory discussions that concern the femtech industry.
Our practical expertise is vital to helping regulators understand legislative gaps and weaknesses that can harm consumers, while also developing innovative solutions that won’t suppress innovation.
Only through public-private partnerships can we make our voices heard and become drivers of the standards and legislation that will someday govern our industry.
Bethany Corbin is a healthcare innovation and femtech attorney on a mission to help thought-leading companies revolutionise women’s health. Through her company, FemInnovation, Corbin partners with emerging companies at the forefront of healthcare transformation to ensure they are building robust, scalable, and legally compliant businesses focused on enhancing health equity.
Newsletter
Sign up for free weekly updates
The latest femtech news, research and investment, straight to your inbox.









